These results suggest the importance of mammary epithelial cells in the cancer microenvironment promoting the migratory activity of breast adenocarcinoma cells and show a novel mechanism through which baicalein inhibits cancer cell motility.
| INTRODUCTION
Metastasis is one hallmark of cancer and the leading cause of death for patients with cancer (Hanahan & Weinberg, 2011) . The metastatic process starts with the invasion of cancer cells into their surrounding host tissues. During this step, cancer cells communicate with their neighboring environment, including non-neoplastic cells, which triggers and promotes their migration and invasion. Various types of normal cells, such as macrophages (Qian & Pollard, 2010) , stromal cells (Gascard & Tlsty, 2016; Hu et al., 2008; Sanz-Moreno et al., 2011) , and adipocytes (Lee, Jung, & Koo, 2015; Nieman et al., 2011; Wang, Gao, Meng, Qiao, & Wang, 2015) have been reported to be involved in cancer cell migration and invasion. Additionally, a recent study proposed the potential importance of normal epithelial cells in cancer cell invasion (Lee, Wu, Gilkes, Aifuwa, & Wirtz, 2015) . Paracrine factors from mammary epithelium-derived cells induce a protrusive morphology and promote the migration of breast adenocarcinoma cells. However, the details of this paracrine interaction are not completely understood. Epithelial cells, from which approximately 90% of human cancers are derived, are a population that closely adheres to cancer cells. Thus, inhibiting interactions between cancer and normal epithelial cells should become a goal for anticancer therapies.
Natural products have been traditionally applied for various diseases including cancer, and great efforts have been made to identify compounds in natural products that
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Genes to Cells TERABAYASHI ET Al. possess anticancer activities. To date, a substantial number of compounds have been derived from various sources, including plants and microorganisms, and their bioactivities against various cancers have been investigated. In fact, camptothecin from Camptotheca acuminate, paclitaxel from Taxus brevifolia, and rapamycin from Streptomyces hygroscopicus have been identified and currently provide great clinical benefits as anticancer therapies (Nobili et al., 2009) .
Baicalein is a member of the flavones, which are a subclass of flavonoids, that were originally isolated from Scutellaria baicalensis Georgi (Liu et al., 2016) . Scutellaria baicalensis Georgi roots have previously been used as an herbal medicine for anti-inflammatory and anticancer therapies. In the last few decades, baicalein has been reported to possess multifaceted biological activities in anti-inflammation, antioxidation, antipyrexia, and antihypersensitivity (Liu et al., 2016) . Furthermore, accumulating evidence has showed the anticancer properties of baicalein against various cancer types, including lung, prostate, liver, and colorectal cancers (Cathcart et al., 2016; Gong et al., 2014; Han et al., 2014; Huang et al., 2017; Kuntz, Wenzel, & Daniel, 1999; Liu, Huang, Cheng, & Lu, 2003; Liu et al., 2016; Pidgeon, Kandouz, Meram, & Honn, 2002; Zhang, Lu, Guo, Zhang, & Meng, 2013; Zheng et al., 2014) .
Baicalein has shown multiple pharmacological activities in breast cancer. It has been reported that baicalein induces apoptosis in several breast cancer cell lines (Lee et al., 2008; Po, Chen, Tsang, & Leung, 2002) , and this proapoptotic activity may be mediated by increased levels of proapoptotic proteins such as Bax and/or decreased levels of the antiapoptotic protein Bcl-2 (Lee et al., 2008) . Baicalein also has been showed to inhibit the progression of breast cancer cells (Gao, Xue, Ma, & Zhang, 2015; Lin, Yang, Shen, & Chen, 2007; Ma et al., 2016) . Baicalein treatment causes a down-regulation of special AT-rich sequence binding protein 1 (SATB1), which controls tumor cell growth by regulating numerous tumorassociated genes and attenuates canonical Wnt signaling by suppressing Wnt-1 and β-catenin expression, resulting in reduced expression of the downstream Wnt target genes, Axin2 and cyclinD1.
Additionally, several lines of evidence indicate inhibitory effects of baicalein on the motility of breast cancer cells. Wang et al. (2013) showed that baicalein inhibits the migration and invasion of the breast adenocarcinoma cell line MDA-MB-231. They further showed that this phenotype was caused by a down-regulation of the matrix metalloproteases (MMPs) MMP-2 and MMP-9 followed by inactivation of mitogenactivated protein kinases (MAPK) signaling. Another group reported that baicalein suppressed 17-β-estradiol-induced migration in the breast adenocarcinoma cell lines MCF-7 and SK-BR-3 (Shang et al., 2015) . These data show the inhibitory activity of baicalein on the motility of breast cancer cells; however, the overall effects of baicalein on the motility of breast cancer cells remain unclear.
In this study, we show that mammary epithelium-derived LN-332 regulates the morphology and motility of breast adenocarcinoma cells. Additionally, we screened a natural compound library and found that baicalein inhibited the morphological changes and migration of breast adenocarcinoma cells induced by conditioned medium from mammary epithelium-derived cells. Baicalein also attenuated the effects of LN-332 on the morphology and motility of breast adenocarcinoma cells. Interestingly, baicalein disturbed the lamellipodia formation that was induced by conditioned medium, but did not affect actin cytoskeleton dynamics that were regulated by exogenously expressed constitutively active forms of Rho family small GTPases. These findings imply novel target(s) of baicalein that is involved in regulating cell motility based on interactions with the tumor microenvironment.
| RESULTS

| LN-332 mediates the paracrine interactions between mammary epitheliumderived cells and breast adenocarcinoma cells
A previous study showed that conditioned medium from mammary epithelial cells promotes the malignancy of breast cancer cells (Lee, Wu, et al., 2015) . Thus, we first verified these findings with the breast cancer cell line MDA-MB-231. To this end, conditioned medium from the human mammary epithelium-derived cell line MCF10A (MCF10A CM) was prepared under serum-free conditions using OPTI-MEM. Then, the human breast adenocarcinoma cell line MDA-MB-231 was treated with MCF10A CM in the absence of serum and their morphologies were observed ( Figure S1a ). As shown in the previous report (Lee, Wu, et al., 2015) , MCF10A CM treatment induced elongated shapes in MDA-MB-231 cells, while treatment with boiled MCF10A CM or conditioned medium from MDA-MB-231 cells themselves did not (Figure S1b-d) . Furthermore, the effect of MCF10A CM on the morphology of MDA-MB-231 cells was dosedependent ( Figure S1e ). We also examined whether MCF10A CM affected the migration of MDA-MB-231 cells using Boyden chamber assays. As expected, the number of migrated MDA-MB-231 cells was significantly increased by MCF10A CM in a dose-dependent manner ( Figure S1f ). These results were consistent with observations in the previous study (Lee, Wu, et al., 2015) and suggest the existence of paracrine interactions between mammary epithelial cells and breast cancer cells.
We next sought to identify the paracrine factors that mediated the effects of MCF10A CM. To this end, MCF10A CM was sequentially separated by conventional column chromatography (Figure S2a Procedures). Then, the fractions that harbored concentrated activities in inducing morphological changes and migration were analyzed by mass spectrometry. Fortunately, the laminin (LN) α-3, β-3, and γ-2 chains were identified as major components in these fractions ( Figure S2c ). The presence of the LN γ-2 chain in MCF10A CM was also confirmed by immunoblotting ( Figure S2d ). LN is a heterotrimeric glycoprotein composed of α, β, and γ chains and is an extracellular matrix protein (Burgeson et al., 1994; Engvall & Wewer, 1996) . Thus, we hypothesized that a trimetric LN-332 could mediate the effects of MCF10A CM on MDA-MB-231 cells.
To address this hypothesis, we treated MDA-MB-231 cells with LN-332 and observed their morphology. Similar to MCF10A CM, cells treated with LN-332 showed a dosedependent elongated morphology (Figure 1a-c) . We also examined the effects of LN-111, LN-511, and LN-521, which compose the mammary basement membrane. Here, LN isolated from Engelbreth-Holm-Swarm tumor cells (EHS-LN) was used as LN-111. Morphological analyses showed that only LN-332, but not other LN nor fibronectin, could induce an elongated morphology (Figure 1c ), demonstrating that LN-332 specifically and sufficiently regulates the morphology of breast adenocarcinoma cells.
We also investigated the effects of LN-332 on the motility of MDA-MB-231 cells. The behavior of MDA-MB-231 cells upon MCF10A CM or LN-332 treatment was monitored by time-lapse microscopy. MDA-MB-231 cells in OPTI-MEM showed a lower migratory activity; however, when they were treated with MCF10A CM, they formed lamellipodia and exhibited robust migration. Furthermore, failure in the retraction of the trailing edge occurred, subsequently causing the elongated morphology (Movies S1 and S2). Tracking analyses showed that MCF10A CM-treated cells migrated faster and farther than untreated cells (Figure 2a-d and Table S1 ). Importantly, LN-332-treated cells showed similar behaviors 
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TERABAYASHI ET Al. (immediate lamellipodia formation, robust migration and an elongated morphology due to impaired retraction of the trailing edge) as MCF10A CM-treated cells (Movie S3). Quantification of migration parameters confirmed the enhanced migratory activity of MDA-MB-231 cell in response to LN-332. The total migration distance and velocity were increased, and there were no significant differences in these parameters between cells treated with LN-332 and MCF10A CM (Figure 2b ,c and Table S1 ). However, it was interesting to note that LN-332-treated cells did not show directional migration, while MCF10A CM-treated cells did ( Figure 2d ). These data showed that LN-332 could mediate at least some of the paracrine interactions between mammary epithelium-derived cells and breast adenocarcinoma cells, although additional factor(s) are required to complement the effects of these paracrine interactions.
| Baicalein suppresses the morphological and migratory changes of MDA-MB-231 cells that are induced by paracrine interactions with the mammary epithelium
Time-lapse analyses showed that the morphological changes induced by MCF10A CM and LN-332 clearly reflected the enhanced migratory activity of MDA-MB-231 cells (Movies S1-S3). These observations gave us the idea to 
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conduct a screen based on the morphological changes of MDA-MB-231 cells induced by MCF10A CM to facilitate the identification of small compounds that influence the aspect of cancer cell motility that is regulated by paracrine interactions.
We sought to identify natural compounds using to this screening strategy, so we used a library containing 96 natural compounds (Table S2) a member of the flavone subclass in flavonoids, clearly suppressed the morphological changes induced by MCF10A CM (Figure 3a,b) . Bufalin, Bufotalin, (E)-capsaicin, curcumin, evodiamine, gomisin N, hirsutine, sennoside A, and sennoside B also inhibited the morphological changes induced by MCF10A CM (Table S2) ; however, because baicalein exhibited the strongest activity, we focused on it in the rest of this study. We next assessed the structure-activity correlation among flavones to confirm the effect of baicalein on MCF10A CM-induced morphological changes ( Figure 3a) . As shown in Figure 3b , baicalein suppressed the elongated morphology of MDA-MB-231 cells in response to MCF10A CM. Additionally, the length of baicalein-treated cells decreased in a dose-dependent manner (Figure 3c ). In contrast, treatment with baicalin, wogonin, or Chrysin did not affect morphological changes upon MCF10A CM treatment (Figures 3c and S3) . Furthermore, no other flavonoids in the library showed significant inhibitory activities (Table S2 and Figure S3 ). We also examined whether baicalein could disturb the effect of LN-332 on the morphology of MDA-MB-231 cells. For this experiment, we pre-treated cells with baicalein for 1 hr and then further treated with LN-332. Morphological analyses showed that baicalein clearly blocked the LN-332-induced elongation of MDA-MB-231 cells in a dose-dependent manner (Figure 3d ). These results show the specific activity of baicalein among flavones in the inhibition of paracrine interactions between mammary epitheliumderived cells and breast adenocarcinoma cells.
As mentioned above, MCF10A CM induced the morphological changes of MDA-MB-231 cells (Movie S2). In addition, MCF10A CM could promote migration of MDA-MB-231 cells ( Figure S1f) . Thus, we also examined the effect of baicalein on MCF10A CM-promoted cell migration. For this experiment, we pre-treated MDA-MB-231 cells with baicalein for 1 hr and then further treated with MCF10A CM. As expected, baicalein treatment resulted in reduced migratory activities in response to MCF10A CM (Figure 4a and Movie S4). Reduced migratory activity in cells treated with baicalein was corroborated by quantifying migration parameters (Figure 4b-d and Table S3 ). Furthermore, we also confirmed a dose-dependent effect of baicalein on the migration of MDA-MB-231 cells in response to either MCF10A CM or LN-332 by the Boyden chamber assay (Figure 4e,f) . These data clearly showed that baicalein inhibited the migration of breast adenocarcinoma cells that is induced by paracrine interactions with mammary epithelium-derived cells.
| Baicalein disrupted MCF10A
CM-induced lamellipodia formation in MDA-MB-231 cells
To investigate the mechanism through which baicalein inhibits the motility of breast cancer cells that is promoted by paracrine interactions with MCF10A cells, we studied lamellipodia formation in detail, because lamellipodia formation at the leading edge is an initial step in the migration of MDA-MB-231 cells that is induced by MCF10A CM (Movie S2). Time-lapse imaging analyses showed that MDA-MB-231 cells began to form lamellipodia immediately after MCF10A CM treatment (Figure 5a and Movies S5 and S6). Lamellipodia became enlarged and their size reached approximately half the total cell area within 10 min after MCF10A CM treatment (Figure 5b,c) . Conversely, baicaleinpre-treated cells showed attenuated responses to MCF10A CM treatment. Baicalein-pre-treatment caused narrow and irregularly shaped lamellipodia to form (Figure 5b ,c and Movie S7). Moreover, the fraction of cells with lamellipodia upon MCF10A CM treatment was decreased in the baicaleinpre-treated group (Figure 5d ). Thus, baicalein appears to target signaling pathways involved in lamellipodia formation that is enhanced by paracrine interactions with mammary epithelium-derived cells. It has been reported that lamellipodia formation is regulated by the Rho family small GTPase Rac1, which reorganizes the actin cytoskeleton downstream of various signaling events (Ridley, Paterson, Johnston, Diekmann, & Hall, 1992) . Additionally, it has also been reported that soluble LN-332 induces Rac1 activation (Russell et al., 2003) . Thus, we examined whether baicalein affected the cell membrane and actin cytoskeleton dynamics regulated by Rac1. We expressed a constitutively active form of GFP-tagged Rac1 (GFP-Val12 Rac1) in HeLa cells and carried out time-lapse analyses of cell shapes upon baicalein treatment. GFP-Val12 Rac1 over-expression caused HeLa cells to spread; however, obvious changes in cell spreading were not observed after baicalein treatment (Figure 6a ). Even at 120 min after baicalein treatment, GFP-Val12-expressing cells remained spread (Movie S8). We also assessed actin dynamics in GFPVal12 Rac1-expressing cells by cotransfecting a plasmid for LifeAct-mCherry, a widely used actin-binding peptide fused to mCherry protein (Riedl et al., 2008) . Actin dynamics in peripheral regions were not disturbed in response to baicalein treatment (Figure 6a and Movie S8), suggesting that baicalein might not target molecules involved in actin dynamics downstream of Rac1. We also examined the effects of baicalein on filopodia formation and stress fibers that are regulated by constitutively active CDC42 (Val12 CDC42) and RhoA (Val14 RhoA), respectively. We over-expressed each constitutively active small GTPase together with LifeAct-mCherry and monitored behaviors of these cellular structures before and after baicalein treatment. As with GFP-Val12 Rac1-expressing cells, membrane and actin cytoskeleton dynamics that were regulated by exogenously expressed constitutively active small GTPases were not influenced by baicalein treatment ( Figure 6b ,c and Movies S9 and S10). Collectively, these data show that baicalein inhibits proteins that regulate Rho family small GTPases in response to paracrine interactions, including LN-332.
| DISCUSSION
In this study, we found that LN-332 mediated the paracrine interactions between mammary epithelium-derived cells and breast adenocarcinoma cells that regulate cancer cell motility and morphological plasticity. Additionally, we established a morphology-based screen that searched a natural compound library for potential antimetastatic drugs that suppressed the morphological changes associated with enhanced cancer cell motility that was promoted by interactions with epithelial cells. Baicalein has been reported to have anticancer activities, including suppressing cancer cell migration and invasion in vitro and in vivo Lin et al., 2007; Ma et al., 2016) , demonstrating the validity of our screening strategy. Data obtained in this study suggested that baicalein could target molecules that are involved in regulating Rho family small GTPases that are downstream of LN-332. The total effects of baicalein on cancer cell motility have not been completely determined; thus, this study provides novel observations for our understanding of how baicalein exerts anticancer activities.
It has been reported that paracrine interactions with mammary epithelium-derived cells promote the malignancy of breast adenocarcinoma cells (Lee, Wu, et al., 2015) . While Lee, Wu, et al. (2015) showed the potential importance of LN in morphological changes and cell migration, purified LN alone could not induce morphological changes or promote Genes to Cells TERABAYASHI ET Al. Genes to Cells
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the migration of MDA-MB-231 cells, indicating that additional secreted proteins from mammary epithelial cells are required to replicate the activity of conditioned medium. In this study, we carried out a mass spectrometry analysis of MCF10A CM fractions separated by conventional chromatography and identified LN-332 as a potent mediator between mammary epithelium-derived cells and breast adenocarcinoma cells (Figures 1 and 2) . In mammary glands, LNs are secreted from myoepithelial cells, which are generally considered to have tumor suppressive roles (Barsky & Karlin, 2005; Hu et al., 2008; Sternlicht, Kedeshian, Shao, Safarians, & Barsky, 1997) . However, several studies have suggested that myoepithelial cells have oncogenic effects, including promoting invasiveness (Allen, Marshall, & Jones, 2014; Allinen et al., 2004; Gudjonsson et al., 2002; Lo et al., 2017) . While LN-332 showed strong impacts, other LNs contained in the mammary basement membrane could not induce obvious morphological changes in MDA-MB-231 cells (Figure 1 ). Together with the previous studies that showed a role for LN-332 in regulating the motility of breast cancer cells (Carpenter et al., 2009; Kim et al., 2011) , LN-332-mediated paracrine interactions may play specific and critical roles in enhancing the malignancy of breast cancer cells in vivo. As represented by epithelial-mesenchymal transition (EMT), changing the mode of cellular migration allows cancer cells to adapt and invade into their surrounding tissue. Data from clinical investigations have indicated that LN-332 is enriched in the invasion interface of breast invasive ductal carcinoma (Kim et al., 2011) . It could be possible that breast cancer cells use LN-332 not only to promote their migratory activities, but also to adjust their mode of migration so that they can efficiently invade into the adjacent stroma after breaking the mammary basement membrane. Importantly, although LN-332 promoted migration and induced morphological changes in MDA-MB-231 cells, it was not sufficient to complement the activity of MCF10A CM (Figure 2d ). MCF10A cells secrete various factors besides LN-332, such as urokinase-type plasminogen activator (uPA) and galectin-1, which also regulate cell migration (Kulasingam & Diamandis, 2007) . Thus, further investigations are required to find other paracrine factors from mammary epithelium-derived cells that cooperate with LN-332 to control the directional migration of breast cancer cells. Additionally, immunoblotting analysis indicated that an approximately 100 kDa form of the LN γ-2 chain was dominant in MCF10A CM ( Figure S2d ). In contrast, two forms of LN γ-2 chain, approximately 150 and 100 kDa, were detected in purified LN-332. LN subunits undergo proteolytic processing after secretion, and cleavage of the LN γ-2 chain into LN-332 by MMP-2 and MT1-MMP is involved in modulating cell morphology and migration (Giannelli, Falk-Marzillier, Schiraldi, Stetler-Stevenson, & Quaranta, 1997; Koshikawa, Giannelli, Cirulli, Miyazaki, & Quaranta, 2000; Koshikawa, Minegishi, Sharabi, Quaranta, & Seiki, 2005) . Thus, the proteolytic processing status of LN subunits might influence the activity of purified LN-332 with regard to its ability to regulate motility.
Recently, great attention has been paid to the effects of flavones on the migration of breast cancer cells. Baicalin, a component from S. baicalensis Georgi root extract, has been reported to inhibit the migration of MDA-MB-231 cells in vitro and in vivo by down-regulating MMP-2, MMP-9, uPA, and uPA receptor expression by blocking of p38MAPK signaling (Wang et al., 2013) . Wogonin, which is isolated from Scutellariae radixin, down-regulates and inactivates MMP-9, thus preventing MDA-MB-231 cells from migrating (Chen et al., 2011) . Chrysin disrupts the migration of metastatic triple-negative breast cancer cell lines by down-regulating MMP-10 and EMT-related genes (Yang et al., 2013) . The effects of baicalein on cancer cell migration were previously reported. Baicalein inhibits not only the expression and secretion of MMP-2 and MMP-9, but also EMT via down-regulating SATB1 expression and Wnt/β-catenin signaling, which results in reduced migratory activities in MDA-MB-231 cells Lin et al., 2007; Ma et al., 2016) . These reports suggested the possibility that a certain subclass of flavones shares common molecular targets and/ or signaling pathways that suppress cancer cell migration. However, we found that only baicalein (and not any other flavone tested) inhibited the morphological changes of breast adenocarcinoma cells following MCF10A CM treatment (Figure 3 ). Baicalein showed rapid and consistent effects against MCF10A CM and LN-332 treatment (Figures 3 and  4) . Particularly, baicalein disrupted lamellipodia formation in response to MCF10A CM treatment ( Figure 5 ), clearly demonstrating that the inhibitory effect of baicalein on cell migration is independent on transcription or protein synthesis. These findings suggest specific and unique activities of baicalein in breast adenocarcinoma cells against paracrine interactions with mammary epithelium-derived cells.
The most important issue to be addressed is to identify target molecules of baicalein that regulates the motility of breast cancer cells in response to paracrine interactions. The key observation for resolving this question is the disrupted lamellipodia formation following baicalein treatment ( Figure 5 ). MCF10A CM and LN-332 treatment immediately induced lamellipodia formation in MDA-MB-231 cells (Figure 2 ), suggesting that these stimuli activate Rac1 in breast adenocarcinoma cells. This idea is also supported by the observation that membrane retraction at the trailing edge was impaired in MCF10A CM-and LN-332-treated cells (Movies S2 and S3) . Activation of RhoA and its effector protein Rhoassociated protein kinase is required to complete trailing edge retraction (Shinohara et al., 2012) , and Rac1 and RhoA mutually antagonize each other in controlling the migratory modes of cancer cells, which are translated to morphological changes (Guilluy, Garcia-Mata, & Burridge, 2011) . Thus, impaired trailing edge retraction in MCF10A CM-or LN-332-treated cells reflects Rac1 activation. Baicalein treatment resulted in narrower and incomplete lamellipodia in response to MCF10A CM ( Figure 5 ). Collectively, these observations suggest that Rac1 activity is suppressed by baicalein. Additionally, baicalein did not affect the membrane or actin dynamics induced by exogenously expressed Rho family small GTPases (Figure 6 ). Thus, baicalein might target proteins that regulate Rac1 activity, but not the regulatory machinery of the actin cytoskeleton downstream of Rac1. To date, various proteins have been reported to regulate Rac activity, and among them, Rac1 guanine nucleotide exchange factors (GEFs) are fascinating candidates, because they can directly activate Rac1 and some Rac-GEFs are activated by interactions between LNs and integrins (Huveneers & Danen, 2009) . Additionally, the tyrosine kinases FAK and Src activate Rac1 by activating Rac-GEFs (Huveneers & Danen, 2009 ). These tyrosine kinases become activated upon integrin clustering following interactions with LNs (Schaller et al., 1994) . Thus, we examined whether baicalein inhibited the activation of these tyrosine kinases. However, we could not see any significant inhibitory effect of baicalein on FAK or Src activation in response to LN-332 using phospho-specific antibodies on Western blots (data not shown). Thus, it will be interesting to examine whether baicalein regulates Rac-GEF activity. Further studies are required to uncover the molecular mechanism(s) through which baicalein inhibits the enhanced cancer cell motility that is induced by paracrine interactions with the tumor microenvironment.
| EXPERIMENTAL PROCEDURES
| Reagents and antibodies
The natural compounds library was provided by the Cooperative Research Project of the Institute of Natural Medicine, University of Toyama, Japan. Baicalein and Chrysin were purchased from Wako Chemicals (Richmond, VA, USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively. LN-332 and fibronectin were from ReproCELL (Yokohama, Japan) and BD Biosciences (Franklin Lakes, NJ, USA), respectively. Phalloidin, EHS-LN, and LN-521 were from Thermo Fisher Scientific (Carlsbad, CA, USA), and LN-511 was from Nippi (Tokyo, Japan). Rabbit polyclonal anti-LN γ-2 antiserum was kindly provided by Dr Sasaki (Oita University) and was described previously (Sasaki et al., 2001 ).
| Cell culture and transfection
MDA-MB-231 and HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Nacalai, Kyoto, Japan) supplemented with 10% fetal bovine serum at 37°C in 5% CO 2 . MCF10A cells were cultured in DMEM/F-12 (Thermo Fisher Scientific) supplemented with 5% heat-inactivated horse serum (Thermo Fisher Scientific), 20 ng/ml EGF (Miltenyi Biotec, Bergisch Gladbach, Germany), 10 μg/ml insulin (Sigma-Aldrich), 0.5 μg/ml hydrocortisone (SigmaAldrich), and 100 ng/ml cholera toxin (Sigma-Aldrich) at 37°C in 5% CO 2 . Cells were transfected with Lipofectamine LTX (Thermo Fisher Scientific) according to the manufacturer's instructions. cDNAs encoding constitutively active Val12 Rac1, Val12 CDC42, and Val14 RhoA were subcloned into the pEGFP-C1 vector (Clontech, Mountain View, CA, USA). The LifeAct-mCherry expression plasmid was kindly provided by Dr Watanabe (Kyoto University) and was described previously ( Higashida et al., 2013) .
| Preparation of conditioned medium
To prepare conditioned medium, MCF10A cells were cultured in 100-mm culture dishes until confluent. Then, the cells were washed with OPTI-MEM (Thermo Fisher Scientific) three times, and the culture medium was replaced with OPTI-MEM. After culturing for 2 days, conditioned medium was collected and centrifuged at 4,000 × g for 30 min to remove debris.
| Migration assay
Cell migration assays were carried out in Boyden chambers. MDA-MB-231 cells were trypsinized, washed twice with OPTI-MEM, and then seeded at 5 × 10 4 cells per well in OPTI-MEM. MCF10A CM or LN-332 was added to the lower chamber. For baicalein treatments, the inhibitor was added to both upper and lower chambers at the indicated concentrations. After 16-hr incubation, cells that had migrated onto the lower surface of the filters were stained with 0.5% crystal violet in 20% methanol and counted. diluted 20-fold with buffer A. These dilutions were then loaded onto hydroxyapatite (Bio-Rad, Hercules, CA, USA) columns equilibrated with buffer B, and the columns were sequentially washed with 10-column volumes of buffer B with 0.5 M NaCl. Proteins were eluted with a linear gradient from 0.02 to 0.5 M sodium phosphate (pH 7.2). After re-examining their activities, fractions with high activity in protrusion formation and promoting migration (nos. 17-21) were diluted 20-fold with buffer C (10 mM Tris-HCl [pH 8.0], 1 mM DTT, 1 mM PMSF, and 1 mM EDTA). These dilutions were then separated on a HiTrap Heparin HP column (GE Life Sciences) equilibrated with buffer D (10 mM Tris [pH 8.0] and 1 mM DTT). The columns were washed with 10-column volumes of buffer A, and proteins were eluted with a linear gradient from 0 to 0.5 M NaCl in buffer D. All preparative chromatography steps were carried out on an AKTApurifier (GE Life Sciences). Fractions were examined for their activities and analyzed by SDS-PAGE and silver staining with the SilverQuest Silver Staining Kit (Thermo Fisher Scientific). Proteins in Fraction No. 17 were precipitated with TCA, dissolved in 8 M urea, reduced, alkylated, and digested with trypsin (Promega, Madison, WI, USA) for 16 hr at 37°C. The digests were desalted using GL-Tip SDB (GL Sciences). LC-MS/MS analysis of the resultant peptides was carried out on an EASY-nLC 1200 UHPLC connected to a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) as described previously (Ishikawa et al., 2016 ).
| Protein purification
| Immunoblotting
Immunoblotting was carried out as previously described (Terabayashi et al., 2007) . Briefly, cells were lysed with SDS sample buffer, then separated by SDS-PAGE, and transferred onto polyvinylidene difluoride membranes. Membranes were blocked with 0.5% fat-free dry milk in TBS with 0.05% Tween-20, incubated with primary antibodies and then with HRP-conjugated anti-mouse IgG or anti-rabbit IgG antibodies (GE Life Sciences).
| Fluorescence imaging and timelapse microscopy
For immunofluorescence staining, cells seeded onto coverslips were fixed with 4% formaldehyde in phosphatebuffered saline for 10 min and incubated for 30 min with phalloidin (Thermo Fisher Scientific). Coverslips were then washed with phosphate-buffered saline, mounted, and examined using a confocal scanning laser microscopy (SP8; Leica, Wetzlar, Germany) equipped with a 60× plan lens. Images were processed with Adobe Photoshop software. For timelapse analysis, cells seeded onto 3.5-cm glass-bottom culture dish (Asahi Techno Glass Co., Tokyo, Japan) were observed every 5 min using a confocal scanning laser microscopy equipped with a temperature-and CO 2 -controlled stage-top live cell incubator (Tokai Hit, Fujinomiya, Japan). Cell migration was measured by tracking the position of each cell over time with ImageJ software using the "Manual Tracking" plug-in.
| Statistical analysis
Results are shown as the mean ± SEM in Figures 1c, 2e , 3c-d, and 4e-f and the mean ± SD in Figures 2b-d, 4b-d , and 5c. All statistical analyses were carried out with the twotailed Student's t test.
